Drug intelligence / Profile preview

EX-044

Development stage: Preclinical
Lead developer: Excelsior
Modality: Small Molecules

Overview

EX-044 is a small molecule inhibitor of the Transforming Growth Factor-beta (TGF-β) pathway currently under preclinical development by Excelsior Group. It is specifically being investigated for the treatment of Wilson's disease, a rare genetic disorder that leads to copper poisoning in the body, particularly affecting the liver and brain. Within Excelsior's TGF-β Research Center, EX-044 is described as a candidate for rare diseases utilizing a mechanism of action distinct from current therapeutic options, likely aimed at mitigating the tissue fibrosis and organ damage associated with the progression of Wilson's disease.

Targets

TGFB (GARP–latent transforming growth factor beta 1 complex)

Beyond the preview

Go deeper on EX-044.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EX-044.

Explore the full profile